CJC-1295 With DAC vs Without DAC: The Evidence Distinction Researchers Should Understand

For laboratory research use only. Not for human or veterinary use. Not a medicinal product.

What Is CJC-1295, and Why Does the DAC Distinction Matter for Research?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), engineered to overcome the rapid enzymatic degradation that limits native GHRH(1-44) in experimental settings. The compound exists in two structurally distinct variants — with and without a Drug Affinity Complex (DAC) — and the difference between them is far more consequential than a simple labelling distinction. For research purposes, selecting the wrong variant for a given study design can fundamentally misrepresent the biology under investigation, which is why researchers should develop a precise understanding of each form before proceeding.

The DAC moiety determines not only the molecule's pharmacokinetic profile but also the nature of GH secretion it models. Understanding this distinction is foundational to rigorous GHRH analogue research and is summarised in detail within the CJC-1295 evidence dossier.

How Does the DAC Moiety Alter the Molecule's Behaviour in Research Models?

The Drug Affinity Complex is a lysine-maleimido propionic acid addition that enables CJC-1295 with DAC to form a covalent bond with circulating serum albumin. This dramatically extends the circulating half-life to an estimated 6–8 days, compared with the 30–60 minute half-life of CJC-1295 without DAC. In research terms, this is not merely a quantitative difference — it is a qualitative one.

With DAC present, GH secretion in experimental models becomes prolonged and tonically sustained rather than discrete and pulsatile. Early published work by Jetté et al. (2005) [VERIFY] demonstrated that the albumin-binding strategy produced a sustained elevation in circulating GH and IGF-1 concentrations in animal models, persisting for several days following a single exposure. This profile has value in specific experimental scenarios — for instance, when investigators are modelling sustained somatotrophic signalling — but it diverges meaningfully from endogenous GHRH physiology.

By contrast, CJC-1295 No DAC (modified GRF 1-29) retains the pulsatile kinetic signature of endogenous GHRH. Its four amino acid substitutions (Tyr at position 1, Ala at position 2, Ala at position 15, and Ala at position 27 — relative to native GHRH) [VERIFY] confer resistance to dipeptidyl peptidase IV (DPP-IV) and other plasma proteases, without disrupting the receptor's capacity to respond in a time-limited, pulse-appropriate manner.

What Is Modified GRF 1-29 and How Does It Relate to CJC-1295 No DAC?

Modified GRF 1-29 and CJC-1295 No DAC are functionally synonymous terms in the research literature. Both refer to the same 29-amino-acid sequence representing the bioactive fragment of GHRH, carrying the four stabilising substitutions noted above. The terminology differs primarily by convention: "modified GRF 1-29" is favoured in earlier pharmacological literature, while "CJC-1295 No DAC" became the more common commercial and research-grade label.

This semantic ambiguity has practical implications for literature searches. Researchers conducting systematic reviews or meta-analyses on GHRH analogue studies should include both terms as search strings to avoid missing relevant preclinical data. For clarity and consistency, Nexyra Lab's research documentation uses CJC-1295 No DAC to denote the DAC-free, pulsatile variant throughout product listings and the associated evidence dossier.

What Do Published Studies Reveal About GH Pulse Kinetics Between the Two Variants?

The mechanistic distinction between DAC and No DAC variants is best understood through their respective GH secretion profiles in preclinical models. The table below summarises the key kinetic parameters reported across available published literature, for reference in study design planning.

Table 1. Comparative kinetic and mechanistic parameters for CJC-1295 variants. Sourced from published preclinical literature; researchers should cross-reference primary sources. [VERIFY individual values]

Research published by Alba et al. (2006) [VERIFY] in animal cohorts demonstrated that CJC-1295 with DAC produced statistically significant, multi-day GH and IGF-1 elevations relative to vehicle controls, with a dose-dependent profile that was not replicated by the shorter-acting analogue on equivalent schedules. This is a critical distinction: the two variants are not interchangeable in study design, and conflating them could introduce systematic error into experimental outcomes.

Why Is Pulsatile GH Signalling Relevant to GHRH Analogue Research?

Endogenous GH is not secreted continuously — it is released in discrete, high-amplitude pulses, predominantly during slow-wave sleep and in response to physiological stimuli. The pulsatile pattern is itself biologically meaningful: downstream hepatic and peripheral responses to GH differ depending on whether signalling is pulsatile or continuous. In male rodent models, for example, pulsatile GH exposure is associated with sex-specific patterns of hepatic gene expression that are abolished when GH is delivered in a continuous profile [VERIFY].

This has direct relevance to research design. Investigators studying GHRH receptor (GHRHR) signalling, somatotroph responsiveness, or downstream IGF-1 production in the context of physiological GH rhythms should select CJC-1295 No DAC, as its kinetic profile preserves the temporal characteristics of the endogenous signal. Studies that deliberately seek to model tonically elevated GH — for instance, in metabolic or body composition research contexts — may instead find the DAC variant more appropriate for their experimental questions.

Researchers interested in how GHRH analogues compare to other growth axis peptides may also find the Ipamorelin evidence dossier useful, as ipamorelin represents a structurally distinct approach to GH secretagogue research via the ghrelin receptor rather than GHRHR.

What Are the Key Considerations for Research-Grade Peptide Selection?

Selecting between CJC-1295 variants requires clarity on three investigative axes: the biological question, the experimental model, and the kinetic profile needed to answer the question rigorously.

Biological question: Is the research question concerned with pulsatile GHRH receptor activation, or with the downstream consequences of sustained somatotrophic signalling? The former warrants the No DAC variant; the latter may warrant the DAC form.

Experimental model: In vitro receptor binding assays, somatotroph cell cultures, or short-duration pulse experiments are well-suited to the No DAC variant. Long-duration in vivo preclinical protocols may require the sustained kinetics of the DAC form.

Peptide quality and purity: Regardless of variant, research-grade purity is non-negotiable for reproducible data. Researchers sourcing GHRH analogues should consult supplier certificates of analysis and verify identity by mass spectrometry or HPLC. Guidance on evaluating research peptide quality is available in Research Peptides UK: What They Are, How They're Tested & What to Look For.

For researchers whose protocols involve lyophilised peptide reconstitution, proper handling methodology is critical to maintaining structural integrity. A detailed procedure is outlined in How to Reconstitute Research Peptides: Step-by-Step Guide with Bacteriostatic Water, which covers compatibility with Bacteriostatic Water (BAC Water) for maintaining sterility in multi-use research vials.

How Does CJC-1295 Research Intersect With Broader Peptide Research Programmes?

GHRH analogue research does not exist in isolation. The GH axis interfaces with metabolic, inflammatory, and connective tissue pathways that are the subject of parallel peptide research programmes. Tesamorelin, another GHRH analogue with a distinct structural profile, is reviewed in the article Tesamorelin: Research on Cognitive Function and Endocrine Effects and within the Tesamorelin evidence dossier, offering a useful comparator for investigators evaluating GHRH analogue pharmacology more broadly.

Researchers are also encouraged to review The Peptide Problem: Hype Outpaces Evidence for Popular Injectables, which examines how unsubstantiated claims in popular discourse can distort the scientific literature landscape — a relevant concern when designing literature reviews around compounds with both research and non-research circulation.

Summary: Choosing the Right CJC-1295 Variant for a Given Research Protocol

The distinction between CJC-1295 with DAC and CJC-1295 without DAC is mechanistically precise and experimentally significant. The DAC-containing form produces sustained, albumin-mediated somatotrophic signalling; the DAC-free form replicates pulsatile GHRH physiology with a short half-life appropriate for receptor-level and pulse-kinetic studies. Neither variant is universally superior — the appropriate selection depends entirely on the experimental question.

Investigators requiring the pulsatile GHRH analogue profile should ensure they are sourcing authenticated CJC-1295 No DAC, and should design their protocols with its 30–60 minute kinetic window in mind. All relevant published literature for study planning is collated in the CJC-1295 evidence dossier.

Research Disclaimer

All Nexyra Lab products are for in vitro research and laboratory use by qualified researchers only. They are not approved by the MHRA, FDA, EMA, or any regulatory authority for human or veterinary use. This article summarises published scientific literature for research planning purposes only and does not constitute medical advice.